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Abstract
Background: One–fifth of patients with seemingly ‘curable’ pancreatic ductal adenocarcinoma (PDA) experience an early
recurrence and death, receiving no definable benefit from a major operation. Some patients with advanced stage tumors
are deemed ‘unresectable’ by conventional staging criteria (e.g. liver metastasis), yet progress slowly. Effective biomarkers
that stratify PDA based on biologic behavior are needed. To help researchers sort through the maze of biomarker data, a
compendium of ,2500 published candidate biomarkers in PDA was compiled (PLoS Med, 2009. 6(4) p. e1000046).
Methods and Findings: Building on this compendium, we constructed a survival tissue microarray (termed s-TMA)
comprised of short-term (cancer-specific death ,12 months, n = 58) and long-term survivors (.30 months, n = 79) who
underwent resection for PDA (total, n = 137). The s-TMA functions as a biological filter to identify bona fide prognostic
markers associated with survival group extremes (at least 18 months separate survival groups). Based on a stringent
selection process, 13 putative PDA biomarkers were identified from the public biomarker repository. Candidates were tested
against the s-TMA by immunohistochemistry to identify the best markers of tumor biology. In a multivariate model, MUC1
(odds ratio, OR = 28.95, 3+ vs. negative expression, p = 0.004) and MSLN (OR= 12.47, 3+ vs. negative expression, p = 0.01)
were highly predictive of early cancer-specific death. By comparison, pathologic factors (size, lymph node metastases,
resection margin status, and grade) had ORs below three, and none reached statistical significance. ROC curves were used
to compare the four pathologic prognostic features (ROC area = 0.70) to three univariate molecular predictors (MUC1, MSLN,
MUC2) of survival group (ROC area = 0.80, p = 0.07).
Conclusions: MUC1 and MSLN were superior to pathologic features and other putative biomarkers as predicting survival
group. Molecular assays comparing cancers from short and long survivors are an effective strategy to screen biomarkers and
prioritize candidate cancer genes for diagnostic and therapeutic studies.
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Introduction
While pancreatic ductal adenocarcinoma (PDA) is typically
aggressive as compared to most other cancers, the disease is
comprised of a range of biological phenotypes. Roughly 20% of
patients who undergo resection will live at least 5 years, and a
similar percentage of patients will recur early after resection and
die of disease within a year [1–4]. At the genomic level, each PDA
acquires a unique constellation of somatic mutations [5].
Molecular diversity at the RNA and protein levels is even more
complex. Despite the genotypic and phenotypic diversity in PDA,
there are no reliable or clinically relevant prognostic biomarkers
that stratify the disease based on predicted outcome.
Pathology reports include basic information regarding the stage
and grade of the tumor, and currently provide the best available
prognostic information. Conventional pathologic features remain
the prognostic gold standard (e.g. lymph node status and histologic
grade). However, across multiple large studies, adjusted hazard
ratios for pathologic features are below two [6–8]. Similarly, in a
validated pancreatic cancer nomogram, adverse pathologic
features contribute less than 10% to 3-year survival predictions
[9]. Serum CA19-9 is equally limited as a prognostic marker [10–
12]. Prognostic information with such minimal predictive value
cannot reliably inform treatment decisions. Furthermore, a
complete set of pathologic data is only available for patients with
resected cancers, which comprise a minority of patients with PDA.
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Improved prognostic information is a priority of cancer
research. First, accurate prognosis informs discussions between
oncologists and patients about the natural history of pancreatic
cancer. Second, the information can guide treatment decisions
with implications for both quality of life and cancer-related
outcomes. The most biologically aggressive PDAs (such as those
that recur soon after resection) are best treated initially with
systemic therapy, as opposed to major surgery. Pancreatic surgery
delays systemic treatment by a minimum of 2 months and exposes
the patient to substantial operative risk with little expected benefit.
On the other hand, patients with indolent cancers with
oligometastatic disease may benefit from an aggressive surgical
approach, as has become standard of care in selected patients with
metastatic colorectal cancer [13]. Third, prognostic biomarkers
provide mechanistic insights into cancer development. Fourth,
they serve as molecular targets for novel treatment strategies such
as vaccine [14], antibody [15], and promoter-driven gene
therapies [16].
High impact studies based on hundreds of patient samples have
improved prognostic capabilities in multiple cancer types (e.g.
lung, prostate, colon, and breast) [17–20]. Studies of similar
magnitude and scope have proven difficult in pancreatic cancer
due to less available tissue for study and less biological
heterogeneity between tumors. Perhaps the most informative
prognostic study to date in PDA identified a panel of 6 prognostic
markers based on gene expression differences between localized
PDA and autopsy specimens (n = 30) [21]. The rationale behind
the study design was that the two study groups represented
different ends of PDA extremes. In fact, the groups were actually
distinguished by disease stage (i.e. early vs late), as opposed to
biologic behavior (i.e. aggressive vs indolent). The localized group
actually had a median survival of just 9 months, which is
considered a short survival period post-resection [6].
In the present study, we used immunohistochemistry to
interrogate a dichotomous set of resected PDAs (n= 137)
comprised exclusively of aggressive (cancer-specific survival ,12
months) and relatively less aggressive (cancer-specific survival .30
months) cancers, for true predictors of survival. A panel of 13
promising PDA biomarkers was selected from literally thousands
of published PDA candidate biomarkers using a rigorous selection
strategy (described in detail below), from on a public compendium
of PDA biomarkers (Figure 1) [22]. Using this approach, we
discounted 11 putative PDA biomarkers as prognostic markers.
However, two proteins, mesothelin (MSLN) and mucin 1, cell
surface associated (MUC1), were robust predictors of survival
group and surpassed conventional pathologic features as prognos-
tic factors. In this study, we demonstrated the utility of a large-
scale, high throughput immunohistochemistry (IHC) based-assay




This study was approved by the Memorial Sloan-Kettering
Cancer Center (MSKCC) institution review board. Patients were
included if they underwent a pancreatic resection for invasive
tubular type (conventional) ductal adenocarcinoma (PDA) after the
year 2000, and either died of disease within 1 year of resection
(short survival) or survived at least 30 months (long survival). The
specific survival boundaries were chosen for two reasons: first, to
yield groups that were sufficiently powered for the analysis, yet had
comparable sample sizes to each other; second, so that that the
time interval between the two survival groups (at least 1.5 years in
the present study) emphasized tumor biology over treatment
related determinants of survival. For instance, adjuvant treatment
provides a survival benefit of roughly 3 months for PDA [23], and
therefore should not dictate survival groups as defined here, except
in rare cases. Similarly, recovery rates from surgery are variable,
but patients who survive pancreatic resection generally return to
their preoperative baseline, or suffer from disease-related symp-
toms [24]. The records of each patient in the short-term survival
group were meticulously reviewed, and only patients who died
from pancreatic cancer (and not complications from surgery) were
included in the study. Patients with invasive cancer arising from an
intraductal papillary mucinous neoplasm, colloid carcinoma,
acinar cell carcinoma, and other less common variants of
adenocarcinoma were excluded.
Clinicopathologic Information
Clinicopathologic information was extracted from the institu-
tional pancreatic tumor database and from electronic patient
records. Relevant clinical variables included postoperative che-
motherapy, radiation therapy, and patient survival. Pathologic
data included lymph node status (positive vs. negative), tumor
differentiation (poor vs. moderate/well), size ($3 cm vs. ,3 cm),
and resection margin status (positive vs. negative). Microscopic
disease at the pancreatic neck, bile duct, duodenum, and uncinate
margins were categorized as positive.
Tissue Preparation
The TMA was constructed from tissue cores obtained from
formalin-fixed, paraffin embedded tissue blocks in 151 patient
samples. In all cases, tissue samples were derived from resected
primary ductal adenocarcinomas of the pancreas. The technician
placed the samples on the TMA in a blinded fashion ensuring that
IHC interpretation by the study investigators was unbiased. The
TMA was constructed as follows: a representative block of tumor
was obtained and a corresponding H & E stained slide was
examined under a microscope for foci of high neoplastic
cellularity. Triplicate cores were taken from the index blocks
Figure 1. Algorithm for the selection of candidate biomarkers
from a large public dataset of pancreatic cancer biomarkers
[22].
doi:10.1371/journal.pone.0040157.g001
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and transferred to a virgin block for TMA processing with an
automated tissue array machine (ATA-27, Beecher Instruments,
Silver Spring, MD). TMA sections were then cut from the block in
preparation for immunohistochemistry experiments.
Selection of Biomarkers
A published compendium of putative pancreatic cancer
biomarkers based on a comprehensive literature search lists
2,516 overexpressed genes (,10% of the genome) in pancreatic
cancer [22]. Due to the overwhelming number of candidate
biomarkers, we designed a strategy to select a panel of antibodies
for use against the s-TMA (Figure 1). We pared the list of
possibilities down to 386 candidate genes previously studied using
IHC. The list of IHC biomarkers in PDA was then cross-
referenced with our institutional pathology catalogue of 380
optimized antibodies. Our pathology core contained 65 optimized
antibodies against putative PDA biomarkers. Due to the finite
number of unstained histologic sections available from a TMA for
study (,50 in the present resource), we further refined the
selection process by stratifying biomarkers according to the
number of independently published IHC studies cited in the
central biomarker repository. Using this strategy, 13 PDA
biomarkers were identified as the subject of four or more IHC-
based peer-reviewed studies, and additionally were already
optimized in our pathology core (BCL2, CASP3, CCND1, EGFR,
ERBB2, MSLN, MUC1, MUC4, P53,SMAD4, MUC5AC,
BIRC5, and ITGB4). The first 10 were selected for testing in
the present study. In addition, three antibodies were included as
representative samples from the remaining choices of putative
PDA biomarkers: CEACAM6 (2 previous IHC-based publica-
tions), MYC (2 publications), and MUC2 (1 publication). MUC2
was believed to be particularly intriguing due to its association with
indolent pancreatic tumors, in direct contrast to MUC1, which has
been linked with more aggressive pancreatic tumor subtypes
[25,26].
Immunohistochemical Analysis
Immunohistochemical analyses were performed by a standard
streptavidin-biotin-peroxidase procedure. Labeled TMA sections
were subjected to heat-induced epitope retrieval with the Ventana
Discovery XT automated system (Ventana Medical Systems,
Tucson, AZ). Primary antibodies and their dilutions included:
BCL2 (1:100, DAKO, Carpenteria, CA), CASP3 (1:300), CCND1
(1:25, Lab Vision, Fremont, CA), CEACAM6 (1:5, Biogenex, San
Ramon, CA), EGFR (1:100, Zymed, Carlsbad, CA), ERBB2
(1:400, Signet, Princeton, NJ), MSLN (1:100, Vector Labs,
Burlingame, CA), MUC1 (1:100, Vector Labs, Burlingame, CA)
[27], MUC2 (1:100 Vector Labs, Burlingame, CA) [27], MUC4
(1:3000, clone 8G7, a gift from University of Nebraska) [28], MYC
(1:2000, Epitomics, Burlingame, CA), P53 (1:500, DAKO,
Carpenteria, CA), and SMAD4 (1:800, Santa Cruz Bio, Santa
Cruz, CA). The Ventana DABMap Kit was used for antibody
detection.
Immunohistochemical review was performed by an expert
pancreatic pathologist (L.H.T.) and recorded by a different study
investigator (J.M.W). SMAD4, MUC2, and BCL2 were scored as
negative or positive by IHC based on previous scoring strategies
[29]. For all other antibodies, a 4-point scale (from 0 to 3+) was
applied based on the percentage of labeled cancer cells in the tissue
core: 0 (,10% labeled cells), 1+ (11–25%), 2+ (26%–75%), 3+
Table 1. Clinicopathologic features in short- (,12 months) and long-term survivors (.30 months).
Variable Total N=137, N (%) Short survivors N=58, N (%) Long survivors N=79, N (%) P value
Lymph nodes
Negative 38 (28%) 10 (17%) 28 (35%) 0.02
Positive 99 (72%) 48 (83%) 51 (65%)
Hisotologic grade
Well/Moderate 93 (68%) 31 (54%) 62 (78%) 0.003
Poor 44 (32%) 27 (47%) 17 (22%)
Tumor size
,3 cm 48 (36%) 14 (24%) 34 (44%) 0.02
$3 cm 87 (64%) 44 (76%) 43 (56%)
Resection margin
Negative 116 (85%) 48 (83%) 68 (86%) 0.6
Positive 21 (15%) 10 (17%) 11 (14%)
Age
,70 years 72 (53%) 28 (48%) 44 (56%) 0.5
$70 years 65 (48%) 30 (52%) 35 (44%)
Gender
Male 76 (55%) 30 (52%) 46 (58%) 0.5
Female 61 (45%) 28 (48%) 33 (42%)
Length of stay (days), Median (range) 9 (4–40) 9 (5–35) 9.5 (4–40) 0.8
Adjuvant treatment
No 51 (39%) 26 (47%) 25 (32%) 0.1
Yes 81 (61%) 29 (53%) 52 (68%)
doi:10.1371/journal.pone.0040157.t001
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Table 2. IHC analysis in short- (,12 months) and long-term survivors (.30 months).






N=79, N (%) P value
BCL2 Negative 137 (100%) 58 (100%) 79 (100%) –
CASP3 0 85 (62%) 35 (60%) 50 (63%) 0.67
1+ 32 (23%) 16 (28%) 16 (20%)
2+ 18 (13%) 6 (10%) 12 (15%)
3+ 2 (1%) 1 (2%) 1 (1%)
CCND1 0 17 (12%) 8 (14%) 9 (11%) 0.43
1+ 51 (37%) 21 (36%) 30 (38%)
2+ 60 (44%) 23 (40%) 37 (47%)
3+ 9 (7%) 6 (11%) 3 (4%)
CEACAM6 0 14 (10%) 7 (12%) 7 (9%) 0.69
1+ 8 (6%) 2 (3%) 6 (8%)
2+ 12 (9%) 6 (10%) 6 (8%)
3+ 103 (75%) 43 (74%) 60 (76%)
EGFR 0 56 (41%) 24 (41%) 32 (41%) 1.0
1+ 38 (28%) 16 (28%) 22 (29%)
2+ 38 (28%) 16 (28%) 22 (29%)
3+ 5 (4%) 2 (3%) 3 (4%)
ERBB2 0 111 (81%) 50 (86%) 61 (79%) 0.26
1+ 23 (17%) 8 (14%) 15 (19%)
2+ 3 (2%) 0 (0) 3 (4%)
MSLN 0 40 (29%) 8 (14%) 32 (41%) ,0.0001
1+ 31 (23%) 11 (19%) 20 (25%)
2+ 45 (33%) 22 (38%) 23 (29%)
3+ 21 (15%) 17 (29%) 4 (5)
MUC1 0 20 (15%) 1 (2%) 19 (24%) ,0.0001
1+ 31 (23%) 9 (16%) 22 (28%)
2+ 45 (33%) 20 (34%) 25 (32%)
3+ 41 (30%) 28 (48%) 13 (16%)
MUC2 Negative 116 (85%) 54 (93%) 62 (78%) 0.03
Positive 21 (15%) 4 (7%) 17 (22%)
MUC4 0 62 (45%) 23 (40%) 39 (49%) 0.70
1+ 30 (22%) 14 (24%) 16 (20%)
2+ 18 (13%) 9 (16%) 9 (11%)
3+ 27 (20%) 12 (21%) 15 (19%)
MYC 0 51 (37%) 25 (43%) 26 (33%) 0.32
1+ 42 (31%) 19 (33%) 23 (29%)
2+ 38 (28%) 13 (22%) 25 (32%)
3+ 6 (4%) 1 (2%) 5 (6%)
SMAD4 Negative 43 (31%) 23 (40%) 20 (25%) 0.09
Positive 94 (69%) 35 (60%) 59 (75%)
TP53 0 57 (42%) 22 (38%) 35 (44%) 0.21
1+ 17 (12%) 5 (9%) 12 (15%)
2+ 35 (26%) 20 (34%) 15 (19%)
3+ 28 (20%) 11 (19%) 17 (22%)
Approved gene names are listed.
Percentages reflect the fraction in a given column.
B-Cell CLL/Lymphoma 2; Caspase 3; Cyclin D1; Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen); Epidermal Growth Factor
Receptor; V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; Mesothelin; Mucin 1, cell surface associated; Mucin 2, oligomeric mucus/gel-forming; Mucin 4,
cell surface associated; V-myc avian myelocytomatosis viral oncogene homolog; Mothers against decapentaplegic, drosophila, homolog of, 4; Tumor protein p53.
doi:10.1371/journal.pone.0040157.t002
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(.75%). An average score was recorded for each triplicate set. A
total of 14 samples had insufficient neoplastic cellularity for IHC
analysis and were excluded, yielding 137 samples with adequate
tissue for all tested antibodies.
Statistical Analysis
The analysis was performed using Intercooled Stata 8.2.
Categorical variables were tested by the Fisher’s exact test,
continuous variables by the Wilcoxon rank sum test, and standard
logistic regression was performed for multivariate testing. Contin-
uous variables were tested using the rank sum test. A comparison
of multivariate regression models was performed to identify the
best prognostic model using receiver operating characteristic
analysis and the associated Harrel’s C-index (also referred to as
area under the curve or ROC area). In the present analysis, the C-
index measures how well a particular multivariate model of
predictors discriminates between short- and long-term survival
groups. The values ranged between 0 and 1. A value of 0.5
indicates no predictive ability (random prediction) and appears as
a diagonal line on an ROC graph, whereas values above 0.5
indicate good predictability, and appear as curvilinear plots above
the diagonal. When two ROC curves do not intersect, the one
with a higher C-index dominates over the other. All statistics were
two-tailed with a p value ,0.05 indicating statistical significance.
Results
Conventional Pathologic Features
There were 79 (58%) patients in the long-term survivor group
and 58 (42%) in the short-term survivor group. Conventional
pathologic features (lymph node status, histologic grade, size, and
resection margin status) and patient variables (age, gender,
postoperative length of stay, and adjuvant treatment) were
analyzed as predictors of survival group (Table 1). None of the
patient-related factors correlated with survival. Of the pathologic
variables, positive lymph node status (p = 0.02), poor differentia-
tion (p= 0.003), and a tumor size greater than 3 cm (p= 0.02)
were associated with early cancer-specific death in the unadjusted
univariate analysis.
The prognostic accuracy of three different models, as estimated
by the Harrell’s C-index, was compared, graphed and tabulated
(Figure 4). The model that included the three biomarkers (MUC1,
MSLN, and MUC2) was superior to the model including four
conventional pathologic features (lymph node status, histologic
grade, tumor size, and resection margin status), although the
difference just missed statistical significance (p = 0.07). The
combined model with biomarkers and pathologic features
performed the best (p = 0.0001).
Biomarkers
Expression patterns of the 13 candidate prognostic markers (see
the Methods and Figure 1 for details on biomarker selection
strategy) in the two survival groups were tested and compared.
The univariate results are provided in Table 2. Out of 13
candidate genes, only MUC1, MSLN, and MUC2 had statistically
different expression patterns between groups. A trend towards
significance was observed with SMAD4 loss (p = 0.09). Represen-
tative slides labeled with MUC1, MSLN, and MUC2 appear in
Figure 2.
MUC1
A strong association was observed between increased MUC1
protein expression and short survival (p,0.0001). In the total
cohort, 15% of patients had an IHC score of 0, 23% had 1+, 33%
had 2+, and 30% had 3+. The proportions of patients that were in
the short survivor group at each separate IHC score increased in a
linear fashion (slope of linear regression = 0.21, p = 0.002).
Specifically, 5% were in the short survival group with an IHC
score of 0, 29% with 1+, 49% with 2+, and 68% with 3+
(Figure 3A). The negative predictive value was high (95%), as 19
out of 20 patients with absent MUC1 expression in this cohort
survived more than 30 months.
MSLN
As compared to MUC1 expression, the pattern of MSLN
expression in the total cohort was slightly weighted towards lower
IHC scores: 63% of patients had 2+ or 3+ MUC1 labeling while
48% had comparable MSLN labeling (p = 0.02). However, like
MUC1, there was a strong association between MSLN expression
and early cancer-specific mortality (p,0.0001). Again, a linear
relationship was observed between the IHC score and the
proportion of patients in the poor survival group (slope of linear
regression = 0.20, p = 0.02). In the different IHC score categories,
the percentage of patients that were in the short survival group
were as follows: 20% of the patients with an IHC score of 0, 35%
with 1+, 49% with 2+, and 81% with 3+ (Figure 3B).
MUC2
MUC2 expression was associated with long survival in contrast
to MUC1 and MSLN (p= 0.03). MUC2 expression was uncom-
mon overall (15%) in PDA. Short-term survivors expressed MUC2
in just 7% of cases. Long-term survivors expressed MUC2 in a
Figure 2. Representative immunolabeled slides: A) MUC1, 0; B)
MUC1, 3+; C) MSLN, 0; D) MSLN, 3+; E) MUC2, negative; F)
MUC2, positive.
doi:10.1371/journal.pone.0040157.g002
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greater proportion, although expression was still uncommon (22%
of cases).
Multivariate Analysis
A multivariate logistic regression analysis was performed which
included significant univariate biomarker predictors of survival
(MUC1, MSLN, and MUC2) as well as the four commonly
reported pathologic features (Table 3). MUC1 and MSLN were
highly significant in the adjusted model, while MUC2 was not. As
compared to absent expression, odds ratios associated with
incremental MSLN expression were 1.7 (IHC score = 1+), 2.6
(IHC score = 2+) and 12.5 (IHC score = 3+). For MUC1, the
odds ratios were 10.1 (IHC score = 1+), 11.9 (IHC score = 2+)
and 29.0 (IHC score = 3+). The composite p-values for MSLN
and MUC1 were p= 0.01 and p=0.004, respectively. None of the
conventional pathologic features were statistically significant in the
multivariate model. To test whether the high prognostic values of
MUC1 and MSLN were merely an artifact of a multi-tiered
comparison (IHC scores of 0 to 3+), the multivariate model was
repeated after categorizing lymph node metastases in a similarly
tiered fashion (negative, 1, or $2 lymph node metastases).
Adjusted odds ratios for the relevant biomarkers were unchanged;
multiple lymph node metastases predicted poor survival with an
odds ratio of only 3.9 (p = 0.02).
Figure 3. Short survivors (% of total) vs IHC score: A) MUC1 B) MSLN.
doi:10.1371/journal.pone.0040157.g003
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Discussion
Early cancer recurrence and mortality after pancreatic resection
(within one year) remain disheartening experiences for clinicians.
In these instances, patients with seemingly ‘‘resectable’’ disease
have major resections with ‘‘curative intent,’’ yet do not receive
any definable benefit, occasionally at the cost of significant
morbidity or even mortality. Our institutional data suggests this
scenario occurs in one–fifth of patients who undergo pancreatic
resection for PDA [30]. On the other hand, some patients with
metastatic disease have relatively slow growing cancers, and might
benefit from metastasectomy or cytologic reduction. This scenario
is extremely uncommon with PDA, yet there is precedent for an
aggressive surgical approach in selected patients with advanced
but indolent disease [31]. Unfortunately, the present approach to
patients with PDA fails to integrate biologic factors. At the present
time, conventional pathologic features provide the best prognostic
information, yet are not sufficiently reliable to impact treatment
decisions, as the present study shows.
Studies designed to identify reliable prognostic markers face two
particular challenges. First, extrinsic determinants of survival
which are independent of a tumor’s molecular profile confound
biomarker analyses. Consider a scenario in which the difference in
overall survival between two patients after pancreatic resection is
only 3 months. The survival difference may be related to patient
performance status, social factors, medical comorbidities, chemo-
therapy response, treatment toxicity, surgical complications, or a
number of other possibilities. Each of these factors may minimally
contribute to patient survival, and would require a study with very
large statistical power to fully characterize each one. Furthermore,
these survival factors are not typically associated with biomarker
expression patterns (chemotherapy response and toxicity may be
exceptions). The present study minimizes noise from alternative
and less significant survival factors by excluding patients with
intermediate survival (12–30 months). Except for rare instances,
tumor biology would be expected to be the principal driver of
survival groups defined by a time gap of this magnitude (a
minimum of 1.5 years separates short and long survivor groups).
We identified 20 other studies in the literature that analyzed
protein biomarkers using TMAs of PDA (Table 4). Unlike the
present study, these TMA-based studies included all patients
across the survival spectrum, which may be interpreted as a
positive study feature. None of these studies identified any
biomarkers with clinical relevance in PDA. We suggest that a
survival TMA may be better suited for biomarker discovery
investigations in PDA, because it emphasizes tumor biology. The
sample size in the present study compares favorably with other
TMA studies (top quartile). Most important, this study likely
includes the largest number of patients at the survival extremes.
The second challenge for biomarker surveys of PDA with IHC
is to devise a rational strategy to select the best molecular
candidates for study. There are roughly 30,000 human protein-
s, and 10% have been reported as overexpressed in PDA [22].
IHC analyses are limited by the amount of available tissue (one
antibody per TMA section, and roughly 30–50 sections per TMA
block), and therefore a rational candidate biomarker selection
process is required to select the most practical and promising
biomarkers for study. Typically, investigators design experimental
biomarker panels according to either research interests, an
intriguing paper, or a unifying theme such as a common molecular
pathway. As Table 4 illustrates, previous TMA studies in PDA test
a small number of antibodies (median of 2 biomarkers per study;
range, 1 to 18). Only two studies examined more than 4
antibodies.
Biomarker selection in the present study was based on the
recently published and centralized biomarker repository for PDA
[22]. Construction of this dataset was a massive effort which
required 7000 person hours (amounting to nearly one person’s
work per year). The authors identified every study in the literature
that linked a gene or protein to PDA, and then tabulated the index
gene (or protein), the principal assays involved in the study, and
the relevant reference. The authors’ primary goal was to ‘‘develop
a compendium of potential biomarkers that could be systemati-
cally validated by the pancreatic cancer community’’ [22]. Putting
their challenge to action, we analyzed this large dataset using an
Table 3. Multivariate predictors of short-term survival.
Prognostic marker OR 95% CI P value
MSLN negative Ref 0.01
MSLN 1+ 1.65 (0.48, 5.72)
MSLN 2+ 2.64 (0.85, 8.22)
MSLN 3+ 12.47 (2.43, 64.14)
MUC2 negative Ref 0.72
MUC2 1+ 0.77 (0.18, 3.32)
MUC1 negative Ref 0.004
MUC1 1+ 10.12 (1.05, 97.50)
MUC1 2+ 11.91 (1.30, 108.91)
MUC1 3+ 28.95 (2.93, 285.64)
Positive lymph node 2.79 (1.0, 7.83) 0.051
Poor differentiation 2.22 (0.84, 5.88) 0.11
Size$3 cm 2.22 (0.89, 5.52) 0.09
Positive resection margin 2.36 (0.71, 7.85) 0.16
doi:10.1371/journal.pone.0040157.t003
Figure 4. ROC curves of 3 predictive models of survival for the
study cohort: Protein biomarkers and conventional pathologic
features (——, MUC1, MUC2, MSLN, lymph node status,
resection margin status, tumor differentiation); protein bio-
markers only (------, MUC1, MUC2, MSLN); conventional path-
ologic features only (……, lymph node status, resection margin
status, tumor differentiation, size). Values along the indicated
diagonal line (line of no-discrimination) reflect a random guess, with
points above the line being better than random. Harrel’s C-index or area
under the curve (AUC) for each plot is provided. P values refer to
comparisons between the given ROC curve as compared to pathologic
features only.
doi:10.1371/journal.pone.0040157.g004
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algorithm (detailed in Figure 1) [22] that placed increased
importance or weight on the number of previous reports linking
a given biomarker to PDA. A total of 13 biomarkers were
identified using this selection strategy and corresponding antibod-
ies were tested against the s-TMA.
IHC analysis revealed that 10 of the13 candidates were non-
informative as prognostic markers in this study cohort. These
negative observations provide convincing evidence (with the
exception of SMAD4 which missed statistical significance,
p = 0.09) that this group of putative pancreatic cancer biomarkers
are clinically irrelevant for prognosis. In the univariate analysis,
MUC1 and MSLN expression were associated with aggressive
cancer biology (i.e. short survival group) and MUC2 expression
was associated with favorable biology (i.e. long survival group).
Only MUC1 and MSLN were robust prognostic factors in the
multivariate model, adjusting for conventional pathologic features
(Table 3). Diffuse MUC1 and MSLN expression were highly
predictive of short survival (the odds ratios were 12.47 and 28.95,
respectively). Interestingly, the four standard pathology tests had
odds ratios below 3, and none achieved statistical significance in
the multivariate model. An ROC analysis was performed to
estimate the predictive accuracy of three different multivariate
models at distinguishing short and long survival groups (biomark-
ers only; pathologic features only; and a combination of
biomarkers and pathologic features). A trend towards superior
predictive accuracy was observed with the panel of molecular
markers (MUC1, MSLN, and MUC2) over conventional patho-
logic features (AUC=0.81 vs. 0.70, p = 0.07). These data suggest
that biomarkers may actually provide more prognostic insight than
standard prognostic data included in pathology reports.
This study validates MUC1 and MSLN as biomarkers of
aggressive pancreatic cancer biology. The implications of these
findings must be interpreted in the context of the study design, and
the role of these proteins as prognostic markers in the clinical
management of PDA remains uncertain. While each oncoprotein
has been the focus of over 200 studies in PDA, there are no large-
scale studies of tumor samples that have thoroughly examined
them as prognostic biomarkers using a comparable graded IHC
scoring system. Some previous studies have observed survival
differences associated with high and low expressing tumors
(MUC1 or MSLN), but are limited by small sample sizes, the
absence of tiered IHC scoring systems, and unadjusted statistics
[32–34].
Certain biomarkers included in the study had expression
patterns that differed from previous reports. For instance, MSLN
expression (1+ or greater) was observed in 71% of patients with
PDA in the present study (as compared to 85–100% in prior
studies [32,35]) and MUC4 expression (1+ or greater) was
observed in 55% (as compared to 90% in prior studies [36,37]).
Differences between this study and previous ones may be related to
sample size variability (previous studies were smaller) and patient
selection (the present study is enriched with patients at the survival
extremes). We are in the process of validating the results of the
present study in a large dataset that includes patients across the
entire survival spectrum. In addition, differences in immunohis-
tochemical scoring are important. For instance, previous studies of
MSLN and MUC4 defined positive labeling as focal antibody
Table 4. Published tissue microarrays with pancreatic cancer.
1st Author Institution Sample Size # Abs tested Biomarker identified (Approved name)
1) Cao [47] JHH 223 1 SERPINB5
2) Karamitopoulou [48] Athens 210 4 CDKN1B and TP53
3) Yu [49,50] Shanghai 167 4 ATM, TP53, CDKN1A, MDM2
4) Tanaka [51] Tokyo 156 1 CLDN18
5) Present study* MSKCC 137 13 MSLN and MUC1
6) Chen [52] Washington 127 2 ITGB1 and ANXA2
7) Matros [53] Brigham 103 2 KRT20
8) Ben [54] Shanghai 94 2 L1CAM
9) Livosky [55] MGH 91 1 LLGL2
10) Coppola [56] South Florida 82 1 SH3GLB1
11) Yang [57] Xi’an 78 1 PSCA
12) Chung [58] Yale 76 3 FLT1
13) Tong [59] MDA 73 1 LCN2
14) Cates [60] Vanderbilt 68 3 TWIST1
15) Cantile [61] Naples 64 1 HOXD13
16) Marsh [62] Ohio State 56 11 CNN1
17) Yang [63] Xi’an 51 1 S100A6
18) Morse [64] MCC 42 2 ABCC3 and TLR2
19) Gray [65] ACC 35 1 PLK1
20) Wen [66] Yonsei 31 2 POU5F1 and NANOG
21) Pham [67] Toronto 26 18 PTEN and STAT3
Pubmed search: tissue[Title/Abstract] AND microarray[Title/Abstract] AND pancreas and cancer.
Abbs: JHH (Johns Hopkins Hospital), MDA (MD Anderson), MCC (Moffitt Cancer Center), ACC (Arizona Cancer Center), Abs (antibodies).
*The present study is the only one that compared patients with short and long survival.
doi:10.1371/journal.pone.0040157.t004
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reactivity in more than 1% of cancer cells [35,36], while the
present study required at least 10% of cells for an IHC score of 1+.
The implications of this research extend beyond improved
prognostic assessment of tumor samples, and therefore the utility
of the s-TMA strategy is not entirely contingent on validation
studies with large numbers of unselected patients. First, biomarker
discovery based on survival extremes is useful to prioritize cancer
genes for diagnostic and therapeutic research. Since the most
biologically aggressive cancer cells are typically refractory to
conventional agents, it stands to reason that novel treatment
approaches that specifically target aggressive sub-clones are
particularly appealing and warrant further investigation. In
support of this concept, the NCI has identified MUC1 and
MSLN among the most promising targets for cancer vaccine
development, with the former protein listed in the top three [38].
A radiolabeled monoclonal antibody against MUC1 was also
recently evaluated in a phase I/II trial, with a planned phase III
trial to follow [39,40]. Furthermore, promoter-driven cancer gene
therapy which exploits overactive MUC1 and MSLN promoters in
various cancer types has been extensively studied in pre-clinical
cancer models using viral vectors [41–43]. We are currently
pursuing a promoter-driven gene therapy approach against PDA
using a non-viral, biodegradable polymer vector to deliver toxic
nanoparticles [16].
Additionally, both MUC1 and MSLN are present on the cell-
surface with secreted isoforms. Thus, prognostic markers such as
these are potentially detectable in sera or secreted fluids. Reliable
noninvasive tests that correlate with membrane-bound isoforms
may function as surrogate biomarkers to biologically stratify
patients or perhaps select them for targeted therapies. An FDA
approved ELISA test of soluble mesothelin-related proteins
(MesomarkH Assay, Fujirebio Diagnostics, Malvern, PA) holds
great promise as a serum and pleural fluid marker for malignant
pleural mesothelioma [44]. The Mesomark Assay has been
evaluated in a single study of PD; the study was not powered to
test prognostic capability and did not compare levels with tumor
MSLN expression [45]. No studies have examined the prognostic
potential of soluble-MUC1 in PDA.
We are presently evaluating additional candidate prognostic
markers against the s-TMA to further optimize the predictive
model. Based on the strategy used to select candidate markers in
the present study, additional intriguing proteins include MU-
C5AC, BIRC5, and ITGB4. A high-throughput proteomic or
transcriptomic analysis of survival extremes could identify novel
prognostic markers, but is best suited for tumor samples enriched
for neoplastic cells such as tumor cell lines or xenografts (as
opposed to primary tumor tissue such as the samples in this study
with abundant stroma) [46]. A high-throughput molecular analytic
strategy would obviate the need for a pre-assay biomarker
selection process for candidate immunohistochemical markers
such as the one described in Figure 1. The disadvantage is that the
results reflect the molecular profile of a clonal cancer cell
population derived from the original tumor (and likely a
particularly aggressive clone selected for under laboratory
conditions), which may not reflect the biology of the rest of the
tumor. Gene expression analyses comparable to the Oncotype
DxH for breast cancer [18], would likely require very large
numbers of primary tumor samples to determine an effective
prognostic panel, particularly because of less biologic heterogene-
ity with PDA.
Conclusions
This study presents the results of a survival-based TMA (s-
TMA), comprised of patient tumor samples associated with short
and long-term survival after resection for PDA. The s-TMA was
used to identify bona fide protein markers of aggressive tumor
biology. MSLN and MUC1 were highly significant predictors of
early cancer-specific mortality, and were superior to conventional
pathologic features as prognostic markers.
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